002252 上海莱士
已收盘 03-27 15:00:00
资讯
新帖
简况
“券商一哥”2025年净赚300亿元！重仓股名单出炉，你有几个？
华夏时报网 · 08:43
“券商一哥”2025年净赚300亿元！重仓股名单出炉，你有几个？
上海莱士（002252）披露2025年年度报告，3月27日股价上涨0.34%
证券之星 · 03-27 17:33
上海莱士（002252）披露2025年年度报告，3月27日股价上涨0.34%
上海莱士：2026年4月29日召开2025年度股东会
证券日报网 · 03-26 22:09
上海莱士：2026年4月29日召开2025年度股东会
上海莱士(002252.SZ)发布2025年度业绩，归母净利润15.77亿元，同比下降28.10%
智通财经 · 03-26 21:43
上海莱士(002252.SZ)发布2025年度业绩，归母净利润15.77亿元，同比下降28.10%
股市必读：上海莱士(002252)股东户数11.35万户，较上期减少0.49%
证券之星 · 03-25
股市必读：上海莱士(002252)股东户数11.35万户，较上期减少0.49%
常铝股份(002160.SZ)子公司中标1.835亿元上海莱士产能扩建工程机电、净化安装项目
智通财经 · 03-24
常铝股份(002160.SZ)子公司中标1.835亿元上海莱士产能扩建工程机电、净化安装项目
上海莱士：公司研发创新的SR604注射液已进入临床试验阶段
每日经济新闻 · 03-16
上海莱士：公司研发创新的SR604注射液已进入临床试验阶段
股市必读：上海莱士(002252)股东户数11.47万户，较上期增加0.38%
证券之星 · 03-11
股市必读：上海莱士(002252)股东户数11.47万户，较上期增加0.38%
上海莱士：公司名称的确定与变更需综合考量公司核心业务方向、品牌辨识度、客户认知度及相关法律法规要求等多重因素
证券之星 · 03-10
上海莱士：公司名称的确定与变更需综合考量公司核心业务方向、品牌辨识度、客户认知度及相关法律法规要求等多重因素
上海莱士最新公告：下属丰镇市同路单采血浆有限公司取得单采血浆许可证
证券之星 · 03-09
上海莱士最新公告：下属丰镇市同路单采血浆有限公司取得单采血浆许可证
上海莱士：血液制品在临床急救、重症救治等场景中发挥重要临床支持作用
证券之星 · 03-04
上海莱士：血液制品在临床急救、重症救治等场景中发挥重要临床支持作用
上海莱士(002252)2月13日股东户数11.43万户，较上期减少0.76%
证券之星 · 03-02
上海莱士(002252)2月13日股东户数11.43万户，较上期减少0.76%
上海莱士（002252）披露2025年前三季度权益分派实施公告，2月2日股价下跌0.63%
证券之星 · 02-02
上海莱士（002252）披露2025年前三季度权益分派实施公告，2月2日股价下跌0.63%
上海莱士（002252）披露全资子公司获得《药品注册证书》，1月30日股价下跌0.94%
证券之星 · 01-30
上海莱士（002252）披露全资子公司获得《药品注册证书》，1月30日股价下跌0.94%
股市必读：上海莱士（002252）1月28日董秘有最新回复
证券之星 · 01-29
股市必读：上海莱士（002252）1月28日董秘有最新回复
上海莱士：公司核心产品为人源性血液制品
证券之星 · 01-28
上海莱士：公司核心产品为人源性血液制品
上海莱士：公司已建立常态化管控机制
证券之星 · 01-23
上海莱士：公司已建立常态化管控机制
上海莱士：持续优化高管薪酬与绩效考核体系
证券之星 · 01-22
上海莱士：持续优化高管薪酬与绩效考核体系
上海莱士：截至2026年1月20日股东户数为110,824户
证券之星 · 01-22
上海莱士：截至2026年1月20日股东户数为110,824户
上海莱士(002252)1月9日股东户数10.93万户，较上期减少0.09%
证券之星 · 01-19
上海莱士(002252)1月9日股东户数10.93万户，较上期减少0.09%
加载更多
公司概况
公司名称：
上海莱士血液制品股份有限公司
所属行业：
医药制造业
上市日期：
2008-06-23
主营业务：
上海莱士血液制品股份有限公司的主营业务是血液制品的生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白、特异性免疫球蛋白、凝血因子类产品。
发行价格：
12.81
{"stockData":{"symbol":"002252","market":"SZ","secType":"STK","nameCN":"上海莱士","latestPrice":5.85,"timestamp":1774594995000,"preClose":5.83,"halted":0,"volume":28381757,"delay":0,"changeRate":0.0034,"floatShares":6634000000,"shares":6638000000,"eps":0.1448,"marketStatus":"已收盘","change":0.02,"latestTime":"03-27 15:00:00","open":5.77,"high":5.87,"low":5.75,"amount":165000000,"amplitude":0.0206,"askPrice":5.86,"askSize":441,"bidPrice":5.85,"bidSize":3163,"shortable":0,"etf":0,"ttmEps":0.1448,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774834200000},"marketStatusCode":5,"adr":0,"adjPreClose":5.83,"symbolType":"stock","openAndCloseTimeList":[[1774575000000,1774582200000],[1774587600000,1774594800000]],"highLimit":6.41,"lowLimit":5.25,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637984837,"isCdr":false,"pbRate":1.19,"roa":"--","peRate":40.400552,"roe":"4.9%","epsLYR":0.24,"committee":-0.11215,"marketValue":38832000000,"turnoverRate":0.0043,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-03-30。","floatMarketCap":38808000000},"requestUrl":"/m/hq/s/002252","defaultTab":"news","newsList":[{"id":"2623331355","title":"“券商一哥”2025年净赚300亿元！重仓股名单出炉，你有几个？","url":"https://stock-news.laohu8.com/highlight/detail?id=2623331355","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623331355?lang=zh_cn&edition=full","pubTime":"2026-03-29 08:43","pubTimestamp":1774744998,"startTime":"0","endTime":"0","summary":"中信证券重仓股情况近期，券商“一哥”中信证券(600030.SH)正式披露2025年年度报告，整体经营稳健且核心业务多点突破。2025年公司实现营业收入748.54亿元，同比增长28.79%；实现归属于母公司股东净利润300.76亿元，同比增长38.58%，创历史最佳业绩表现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603293687921846.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603293687921846.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["600711","000401","BK0214","LU1655091616.SGD","LU1328615791.USD","BK0235","LU2495084118.USD","LU1997244956.HKD","LU0405327494.USD","BK0046","BK0239","BK0025","BK0242","000822","BK0077","LU0405327148.USD","BK0088","300595","LU1580142542.USD","BK0010","000789","LU1997245094.SGD","BK0276","BK0044","LU1997245177.USD","002981","LU1064131003.USD","LU2148510915.USD","600030","LU2289578879.USD","BK0229","BK0196","BK0012","BK0188","600529","BK0251","LU1255011170.USD","BK0182","BK0028","002252","LU1064130708.USD","BK0186","BK0172","BK0185","LU1781817850.SGD","BK0183"],"gpt_icon":0},{"id":"2622284259","title":"上海莱士（002252）披露2025年年度报告，3月27日股价上涨0.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622284259","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622284259?lang=zh_cn&edition=full","pubTime":"2026-03-27 17:33","pubTimestamp":1774604038,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，上海莱士报收于5.85元，较前一交易日上涨0.34%，最新总市值为388.32亿元。该股当日开盘5.77元，最高5.87元，最低5.75元，成交额达1.65亿元，换手率为0.43%。上海莱士于近日披露《2025年年度报告》。报告显示，2025年末公司总资产为37,781,306,856.26元，归属于上市公司股东的净资产为32,456,025,360.59元。基本每股收益0.24元，稀释每股收益0.24元，加权平均净资产收益率4.90%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700036784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0196","BK0046","BK0028","BK0239","002252"],"gpt_icon":0},{"id":"2622869914","title":"上海莱士：2026年4月29日召开2025年度股东会","url":"https://stock-news.laohu8.com/highlight/detail?id=2622869914","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622869914?lang=zh_cn&edition=full","pubTime":"2026-03-26 22:09","pubTimestamp":1774534140,"startTime":"0","endTime":"0","summary":"证券日报网讯3月26日，上海莱士发布公告称，公司将于2026年4月29日召开2025年度股东会。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-26/doc-inhsiusr8818207.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-26/doc-inhsiusr8818207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0196","002252","BK0188","BK0239","BK0046"],"gpt_icon":0},{"id":"2622686559","title":"上海莱士(002252.SZ)发布2025年度业绩，归母净利润15.77亿元，同比下降28.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622686559","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622686559?lang=zh_cn&edition=full","pubTime":"2026-03-26 21:43","pubTimestamp":1774532616,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海莱士(002252.SZ)发布2025年年度报告，报告期内，公司实现营业收入73.48亿元，同比下降10.13%。实现归属于上市公司股东的净利润15.77亿元，同比下降28.10%。实现归属于上市公司股东的扣除非经常性损益的净利润15.6亿元，同比下降24.25%。基本每股收益为0.24元。拟向全体股东每10 股派发现金红利0.33元(含税)。截至2025年12月末，公司总资产377.81亿元，较上年末增加 12.34%;归属于上市公司股东的净资产324.56亿元，较上年末增加1.66%;资金储备28.4亿元，流动性充足，资产结构稳健。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419876.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"上海莱士(002252.SZ)发布2025年度业绩，归母净利润15.77亿元，同比下降28.10%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002252"],"gpt_icon":0},{"id":"2622097101","title":"股市必读：上海莱士(002252)股东户数11.35万户，较上期减少0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622097101","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622097101?lang=zh_cn&edition=full","pubTime":"2026-03-25 02:24","pubTimestamp":1774376653,"startTime":"0","endTime":"0","summary":"截至2026年3月24日收盘，上海莱士报收于5.83元，上涨1.39%，换手率0.39%，成交量25.96万手，成交额1.51亿元。交易信息汇总资金流向3月24日主力资金净流入373.26万元；游资资金净流出680.73万元；散户资金净流入307.46万元。股本股东变化股东户数变动近日上海莱士披露，截至2026年3月20日公司股东户数为11.35万户，较3月10日减少557.0户，减幅为0.49%。户均持股数量由上期的5.82万股增加至5.85万股，户均持股市值为35.21万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500003726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0196","002252","BK0188","BK0239","BK0046"],"gpt_icon":0},{"id":"2621054611","title":"常铝股份(002160.SZ)子公司中标1.835亿元上海莱士产能扩建工程机电、净化安装项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2621054611","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621054611?lang=zh_cn&edition=full","pubTime":"2026-03-24 15:51","pubTimestamp":1774338691,"startTime":"0","endTime":"0","summary":"智通财经APP讯，常铝股份(002160.SZ)发布公告，近日，公司全资子公司上海朗脉洁净技术股份有限公司(以下简称“上海朗脉”)收到《中标通知书》，确定上海朗脉为上海莱士血液制品股份有限公司产能扩建工程机电、净化安装项目(专业分包)的中标单位，本次中标项目的中标金额合计为1.835亿元，占上海朗脉2024年度经审计营业收入的20.15%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0233","BK0196","BK0239","002252","BK0028","BK0076","002160","BK0046","BK0188"],"gpt_icon":0},{"id":"2619365054","title":"上海莱士：公司研发创新的SR604注射液已进入临床试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2619365054","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619365054?lang=zh_cn&edition=full","pubTime":"2026-03-16 11:55","pubTimestamp":1773633300,"startTime":"0","endTime":"0","summary":"公司将加快推进各阶段临床试验等工作，力争早日实现产品上市。除“SR604”外，公司也正在推进其他全球首创新靶点新机制的抗体药物研发。公司“脱浆”战略着眼于创新突破，在夯实血液制品研发基础的同时，积极向生物制药高附加值领域拓展。前述“SR604”产品、其他研发管线布局以及现有产品新适应扩展是公司落实“拓浆”、“脱浆”战略的重要工作。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-16/doc-inhreeew9826364.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-16/doc-inhreeew9826364.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0239","BK0196","BK0046","002252","BK0188"],"gpt_icon":0},{"id":"2618950517","title":"股市必读：上海莱士(002252)股东户数11.47万户，较上期增加0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618950517","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618950517?lang=zh_cn&edition=full","pubTime":"2026-03-11 01:15","pubTimestamp":1773162911,"startTime":"0","endTime":"0","summary":"截至2026年3月10日收盘，上海莱士报收于6.24元，上涨0.0%，换手率0.34%，成交量22.25万手，成交额1.39亿元。股本股东变化股东户数变动近日上海莱士披露，截至2026年2月27日公司股东户数为11.47万户，较2月13日增加440.0户，增幅为0.38%。户均持股数量由上期的5.81万股减少至5.79万股，户均持股市值为36.39万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031100000565.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0196","BK0028","BK0239","BK0046","002252"],"gpt_icon":0},{"id":"2618606233","title":"上海莱士：公司名称的确定与变更需综合考量公司核心业务方向、品牌辨识度、客户认知度及相关法律法规要求等多重因素","url":"https://stock-news.laohu8.com/highlight/detail?id=2618606233","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618606233?lang=zh_cn&edition=full","pubTime":"2026-03-10 08:48","pubTimestamp":1773103691,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士(002252)03月09日在投资者关系平台上答复投资者关心的问题。投资者提问：公司作为海尔集团的子公司，建议公司更名为上海海尔莱士血液制品股份有限公司，增加公司知名度。上海莱士回复：您好！感谢您对我公司的关心和建议！公司名称的确定与变更需综合考量公司核心业务方向、品牌辨识度、客户认知度及相关法律法规要求等多重因素。长期以来上海莱士品牌在行业内树立起了安全、优质的品牌形象，产品质量也获得了市场的信赖以及认可。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031000005437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","002252","BK0046","BK0028","BK0196"],"gpt_icon":0},{"id":"2618413016","title":"上海莱士最新公告：下属丰镇市同路单采血浆有限公司取得单采血浆许可证","url":"https://stock-news.laohu8.com/highlight/detail?id=2618413016","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618413016?lang=zh_cn&edition=full","pubTime":"2026-03-09 17:14","pubTimestamp":1773047659,"startTime":"0","endTime":"0","summary":"上海莱士(002252.SZ)公告称，全资子公司同路生物制药有限公司收到内蒙古自治区卫生健康委员会下发的《内蒙古自治区卫生健康委关于同意设置丰镇市同路单采血浆站的批复》。近日，丰镇市同路单采血浆有限公司收到《单采血浆许可证》，业务项目包括机采单采普通原料血浆等，设置单采血浆站的血液制品生产单位为同路生物制药有限公司，采浆区域为丰镇市城内。该事项有利于提升公司原料血浆供应能力，对公司长期发展具有积极作用。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900023071.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0196","002252","BK0028","BK0046","BK0239"],"gpt_icon":0},{"id":"2616533703","title":"上海莱士：血液制品在临床急救、重症救治等场景中发挥重要临床支持作用","url":"https://stock-news.laohu8.com/highlight/detail?id=2616533703","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616533703?lang=zh_cn&edition=full","pubTime":"2026-03-04 17:15","pubTimestamp":1772615719,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士(002252)03月04日在投资者关系平台上答复投资者关心的问题。投资者提问：最近区域冲突不断，请问血制品对军方来说是否为强需求？上海莱士回复：您好！感谢您对我公司的关心和支持！血液制品在临床急救、重症救治等场景中，发挥着重要的临床支持作用，是保障患者生命安全的重要医疗资源之一。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400030072.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0196","BK0046","002252","BK0028","BK0239"],"gpt_icon":0},{"id":"2616738768","title":"上海莱士(002252)2月13日股东户数11.43万户，较上期减少0.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616738768","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616738768?lang=zh_cn&edition=full","pubTime":"2026-03-02 17:28","pubTimestamp":1772443736,"startTime":"0","endTime":"0","summary":"证券之星消息，近日上海莱士披露，截至2026年2月13日公司股东户数为11.43万户，较1月30日减少875.0户，减幅为0.76%。在生物制品行业个股中，上海莱士股东户数高于行业平均水平，截至2月13日，生物制品行业平均股东户数为3.46万户。从股价来看，2026年1月30日至2026年2月13日，上海莱士区间跌幅为0.64%，在此期间股东户数减少875.0户，减幅为0.76%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200025420.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0028","BK0239","BK0046","002252","BK0188"],"gpt_icon":0},{"id":"2608857421","title":"上海莱士（002252）披露2025年前三季度权益分派实施公告，2月2日股价下跌0.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608857421","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608857421?lang=zh_cn&edition=full","pubTime":"2026-02-02 18:02","pubTimestamp":1770026524,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，上海莱士报收于6.26元，较前一交易日下跌0.63%，最新总市值为415.54亿元。该股当日开盘6.3元，最高6.32元，最低6.25元，成交额达2.18亿元，换手率为0.52%。上海莱士血液制品股份有限公司于近日披露《2025年前三季度权益分派实施公告》。本次实际现金分红总额为100,504,214.14元，折算每10股现金红利为0.151407元。股权登记日为2026年2月9日，除权除息日为2026年2月10日。公司回购股份69,081,952股不参与本次分红。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200027384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","002252","BK0046","BK0028","BK0239","BK0188"],"gpt_icon":0},{"id":"2607041663","title":"上海莱士（002252）披露全资子公司获得《药品注册证书》，1月30日股价下跌0.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607041663","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607041663?lang=zh_cn&edition=full","pubTime":"2026-01-30 22:30","pubTimestamp":1769783440,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，上海莱士报收于6.3元，较前一交易日下跌0.94%，最新总市值为418.19亿元。该股当日开盘6.34元，最高6.37元，最低6.27元，成交额达2.58亿元，换手率为0.62%。上海莱士近日披露公告显示，其全资子公司同路生物制药有限公司近日收到国家药品监督管理局签发的《药品注册证书》，药品名称为人纤维蛋白原，剂型为注射剂，注册分类为治疗用生物制品，适应症为先天性纤维蛋白原减少或缺乏症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000047434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","BK0028","002252","BK0188","BK0046"],"gpt_icon":0},{"id":"2607974911","title":"股市必读：上海莱士（002252）1月28日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2607974911","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607974911?lang=zh_cn&edition=full","pubTime":"2026-01-29 01:42","pubTimestamp":1769622137,"startTime":"0","endTime":"0","summary":"截至2026年1月28日收盘，上海莱士报收于6.35元，下跌0.63%，换手率0.85%，成交量56.33万手，成交额3.58亿元。董秘最新回复投资者： 1.请问贵公司产品可用于尼帕病毒检测吗？目前，公司无相关产品用于尼帕病毒检测；也暂无与上海药物研究所有合作。此外，公司“脱浆”战略着眼于创新突破，在夯实血液制品研发基础的同时，积极向生物制药其他高附加值领域拓展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900001028.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0196","BK0028","002252","BK0239","BK0188"],"gpt_icon":0},{"id":"2606799566","title":"上海莱士：公司核心产品为人源性血液制品","url":"https://stock-news.laohu8.com/highlight/detail?id=2606799566","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606799566?lang=zh_cn&edition=full","pubTime":"2026-01-28 16:57","pubTimestamp":1769590635,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士01月28日在投资者关系平台上答复投资者关心的问题。公司目前无相关同类的产品，也未开展该类产品的研发。公司核心产品为人源性血液制品，如人血白蛋白、静注人免疫球蛋白、凝血因子类等产品。血液制品在临床急救及相关危急重症场景中发挥着关键的作用。此外，公司“脱浆”战略着眼于创新突破，在夯实血液制品研发基础的同时，积极向生物制药其他高附加值领域拓展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800028528.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0196","BK0239","BK0028","002252","BK0188"],"gpt_icon":0},{"id":"2605647097","title":"上海莱士：公司已建立常态化管控机制","url":"https://stock-news.laohu8.com/highlight/detail?id=2605647097","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605647097?lang=zh_cn&edition=full","pubTime":"2026-01-23 20:51","pubTimestamp":1769172687,"startTime":"0","endTime":"0","summary":"上市公司股价受市场、政策等多重因素影响。公司已建立常态化管控机制，一方面持续跟踪商誉相关标的经营情况，通过优化标的业务布局、强化协同整合、提升运营效率等方式，保障标的盈利能力稳定；另一方面将严格按照会计准则要求，每年年终聘请审计机构和评估机构进行商誉减值测试，及时、准确披露相关情况。每年年末，公司会聘请专业的评估和审计机构对长期股权投资进行减值测试。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300040049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","002252","BK0188","BK0239","BK0046","BK0028"],"gpt_icon":0},{"id":"2605469825","title":"上海莱士：持续优化高管薪酬与绩效考核体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2605469825","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605469825?lang=zh_cn&edition=full","pubTime":"2026-01-22 16:51","pubTimestamp":1769071879,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士01月22日在投资者关系平台上答复投资者关心的问题。制度也明确约定了高管薪酬确定原则、绩效考核体系、方案审批流程等核心条款。未来，公司将积极借鉴优秀公司的实践经验，结合自身经营发展需要，持续科学优化高管薪酬与绩效考核体系，更好地平衡激励效果与股东利益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200026795.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","002252","BK0046","BK0028","BK0196"],"gpt_icon":0},{"id":"2605660324","title":"上海莱士：截至2026年1月20日股东户数为110,824户","url":"https://stock-news.laohu8.com/highlight/detail?id=2605660324","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605660324?lang=zh_cn&edition=full","pubTime":"2026-01-22 16:48","pubTimestamp":1769071700,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士(002252)01月22日在投资者关系平台上答复投资者关心的问题。投资者提问：问下1/20的股东人数上海莱士回复：您好！感谢您对我公司的关心和支持！截至2026年1月20日，公司股东总户数为110,824户。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200026708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002252","BK0046","BK0188","BK0239","BK0196"],"gpt_icon":0},{"id":"2604849741","title":"上海莱士(002252)1月9日股东户数10.93万户，较上期减少0.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604849741","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604849741?lang=zh_cn&edition=full","pubTime":"2026-01-19 17:27","pubTimestamp":1768814877,"startTime":"0","endTime":"0","summary":"证券之星消息，近日上海莱士披露，截至2026年1月9日公司股东户数为10.93万户，较12月31日减少93.0户，减幅为0.09%。在生物制品行业个股中，上海莱士股东户数高于行业平均水平，截至1月9日，生物制品行业平均股东户数为3.44万户。从股价来看，2025年12月31日至2026年1月9日，上海莱士区间涨幅为2.05%，在此期间股东户数减少93.0户，减幅为0.09%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900023292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002252","BK0239","BK0028","BK0046","BK0188","BK0196"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774785536678,"stockEarnings":[{"period":"1week","weight":-0.0282},{"period":"1month","weight":-0.0714},{"period":"3month","weight":-0.0895},{"period":"6month","weight":-0.1221},{"period":"1year","weight":-0.1497},{"period":"ytd","weight":-0.0751}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0563},{"period":"3month","weight":-0.0126},{"period":"6month","weight":0.0224},{"period":"1year","weight":0.1601},{"period":"ytd","weight":-0.0139}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海莱士血液制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"113502人(较上一季度减少0.49%)","perCapita":"58446股","listingDate":"2008-06-23","address":"上海市奉贤区望园路2009号","registeredCapital":"663798万元","survey":" 上海莱士血液制品股份有限公司的主营业务是血液制品的生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白、特异性免疫球蛋白、凝血因子类产品。","listedPrice":12.81},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海莱士(002252)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海莱士(002252)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海莱士,002252,上海莱士股票,上海莱士股票老虎,上海莱士股票老虎国际,上海莱士行情,上海莱士股票行情,上海莱士股价,上海莱士股市,上海莱士股票价格,上海莱士股票交易,上海莱士股票购买,上海莱士股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海莱士(002252)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海莱士(002252)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}